No silver lining in failed Bristol cancer drug trial

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closely watched clinical trial.